查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1621575

尿激酶市场：按类型、剂量强度、适应症和应用分类 - 全球预测 2025-2030

Urokinase Market by Type (Urokinase Powder, Urokinase Solution), Dose Strength (250000 Unit, 5000 Unit), Indication, Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年尿激酶市值为17.6亿美元，预计到2024年将达到18.5亿美元，复合年增长率为5.30%，预计到2030年将达到25.2亿美元。

尿激酶是一种用于溶解血栓的酶，在溶栓治疗中发挥至关重要的作用，特别是对于心肌梗塞和肺动脉栓塞。尿激酶的市场由其在急诊医学中的应用决定，其中快速溶栓提供了关键的挽救生命的治疗。对尿激酶的需求源于其在治疗急性血栓性疾病的有效性，全球心血管疾病发生率的上升推动了需求的成长。该研究涵盖了医院、专科诊所以及用于治疗和实验的实验室。该市场正受到人口老化、医疗保健支出增加以及生物技术进步带来的产品改进等因素的影响。然而，高昂的治疗成本、严格的监管要求以及来自组织胞浆素原原激活剂（tPA）等替代疗法的竞争构成了增长的主要障碍。

主要市场统计
基准年[2023] 17.6亿美元
预计年份 [2024] 18.5亿美元
预测年份 [2030] 25.2亿美元
复合年增长率（%） 5.30%

目前的发展机会在于将尿激酶的应用扩展到新的治疗领域，由于意识的提高和医疗基础设施的改善而在发展中地区增加使用，以及生物製造的潜在发展以降低成本。为了利用这些机会，企业必须注重策略伙伴关係和研发投资，以使尿激酶的应用多样化，同时确保符合监管标准。风险包括潜在的副作用、生物相似药的出现以及原材料供应的波动，这对市场渗透构成了挑战。

创新的重点是提高配方的特异性和功效、个人化药物以实现个人化溶栓治疗，以及改进给药机制。此外，对大规模临床试验的投资可以深入了解尿激酶的更广泛应用，并提供可以对监管机构和付款人产生有利影响的有价值的资料。尿激酶市场是充满活力的，其特点是竞争格局，持续的技术创新以及对具有成本效益的生产和广泛应用的战略重点是持续增长和应对市场挑战的关键。

市场动态：揭示快速发展的尿激酶市场的关键市场洞察

尿激酶市场正因供需的动态交互作用而转变。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 全球肺动脉栓塞和冠状动脉栓塞的盛行率不断上升==。
    • 政府对尿激酶药物的支持性核准
  • 市场限制因素
    • 药物开发成本上升和替代药物的供应
  • 市场机会
    • 持续研发提高尿激酶的适用性
    • 采用先进的药物传递系统增强尿激酶的治疗效果
  • 市场挑战
    • 与尿激酶药物相关的副作用

波特的五力：驾驭尿激酶市场的策略工具

波特的五力框架是了解尿激酶市场竞争格局的关键工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解尿激酶市场的外部影响

外部宏观环境因素在塑造尿激酶市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解尿激酶市场竞争状况

对尿激酶市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵尿激酶市场供应商绩效评估

FPNV定位矩阵是评估尿激酶市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了尿激酶市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，尿激酶市场的策略分析至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开发：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、未开发地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点关注可望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 全球肺动脉栓塞和冠状动脉栓塞的发生率正在增加 =
      • 政府核准尿激酶药物
    • 抑制因素
      • 药物开发高成本且替代品可用性高
    • 机会
      • 持续研发提高尿激酶的适用性
      • 采用先进的药物传递系统来增强基于尿激酶的疗法的功效
    • 任务
      • 与尿激酶药物相关的副作用
  • 市场区隔分析
    • 类型：尿激酶粉因其保质期长而备受青睐
    • 应用：扩大尿激酶作为重要治疗药物在医院的应用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章尿激酶市场：依类型

  • 尿激酶粉
  • 尿激酶溶液

第七章以剂量强度分類的尿激酶市场

  • 25万台
  • 5000 单位

第八章尿激酶市场适应症

  • 导管间隙
  • 冠状动脉栓塞
  • 深层静脉栓塞症
  • 肺动脉栓塞

第九章尿激酶市场：依应用分类

  • 医院
  • 调查机构
  • 专科诊所

第10章美洲尿激酶市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区尿激酶市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲尿激酶市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • 策略伙伴关係带回 Kinlytic：溶栓治疗的突破
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • BBT Biotech GmbH
  • Cerbios-Pharma SA
  • Echelon Biosciences
  • Ilex Life Sciences LLC
  • JCR Pharmaceuticals Co., Ltd.
  • Jiangsu Aidea Pharmaceutical Co., Ltd
  • Jiangxi Haoran Bio-pharma Co., Ltd.
  • Kraeber & Co GmbH
  • Merck KGaA
  • Microbix Biosystems Inc.
  • Midas Pharma GmbH
  • Pfizer Inc.
  • Syner-Med Pharmaceuticals
  • Taj Pharmaceuticals Ltd.
  • Thermo Fisher Scientific Inc.
  • VWR International, LLC
  • Wanhua Biochem Products Co. Ltd.
  • Zydus Lifesciences Limited
Product Code: MRR-0355054AC506

The Urokinase Market was valued at USD 1.76 billion in 2023, expected to reach USD 1.85 billion in 2024, and is projected to grow at a CAGR of 5.30%, to USD 2.52 billion by 2030.

Urokinase, an enzyme used to dissolve blood clots, plays a pivotal role in thrombolytic therapy, particularly in conditions such as myocardial infarction and pulmonary embolism. The market for urokinase is defined by its application in emergency medicine, providing life-saving interventions where rapid clot dissolution is crucial. Necessity arises from its effectiveness in treating acute thrombotic conditions, with a growing demand influenced by the rising incidence of cardiovascular diseases globally. The scope of urokinase extends to hospitals, specialty clinics, and research laboratories where it's used both therapeutically and experimentally. The market is influenced by factors such as an aging population, increasing healthcare expenditure, and advancements in biotechnology driving product enhancement. However, significant growth barriers include high therapy costs, stringent regulatory requirements, and competition from alternative therapies like tissue plasminogen activator (tPA).

KEY MARKET STATISTICS
Base Year [2023] USD 1.76 billion
Estimated Year [2024] USD 1.85 billion
Forecast Year [2030] USD 2.52 billion
CAGR (%) 5.30%

Current opportunities lie in expanding urokinase's application into novel therapeutic areas, increased use in developing regions due to heightened awareness and healthcare infrastructure improvements, and potential development in bio-manufacturing to reduce costs. To capitalize on these opportunities, companies should focus on strategic partnerships and R&D investments to diversify urokinase applications while ensuring compliance with regulatory standards. Risks involve possible side effects, the emergence of biosimilars, and fluctuations in raw material availability, posing challenges to market penetration.

Innovation could focus on enhancing the specificity and efficacy of urokinase formulations, personalized medicine approaches to tailored thrombolytic therapy, and improved delivery mechanisms. Additionally, investments in large-scale clinical trials could provide insights into broader applications of urokinase, contributing valuable data that may favorably influence regulators and payers. The urokinase market is dynamic, characterized by a competitive landscape where continuous innovation and strategic leanings towards cost-effective production and wide-scale application are key for sustainable growth and resilience against market challenges.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Urokinase Market

The Urokinase Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of pulmonary embolism and coronary artery thrombosis worldwide=
    • Supportive government approvals for urokinase-based medications
  • Market Restraints
    • High costs of drug development and availability of alternatives
  • Market Opportunities
    • Ongoing research and development to improve the applicability of urokinase
    • Adoption of advanced drug delivery systems to enhance the effectiveness of urokinase-based treatments
  • Market Challenges
    • Side effects associated with urokinase-based drugs

Porter's Five Forces: A Strategic Tool for Navigating the Urokinase Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Urokinase Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Urokinase Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Urokinase Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Urokinase Market

A detailed market share analysis in the Urokinase Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Urokinase Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Urokinase Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Urokinase Market

A strategic analysis of the Urokinase Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Urokinase Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, BBT Biotech GmbH, Cerbios-Pharma SA, Echelon Biosciences, Ilex Life Sciences LLC, JCR Pharmaceuticals Co., Ltd., Jiangsu Aidea Pharmaceutical Co., Ltd, Jiangxi Haoran Bio-pharma Co., Ltd., Kraeber & Co GmbH, Merck KGaA, Microbix Biosystems Inc., Midas Pharma GmbH, Pfizer Inc., Syner-Med Pharmaceuticals, Taj Pharmaceuticals Ltd., Thermo Fisher Scientific Inc., VWR International, LLC, Wanhua Biochem Products Co. Ltd., and Zydus Lifesciences Limited.

Market Segmentation & Coverage

This research report categorizes the Urokinase Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Urokinase Powder and Urokinase Solution.
  • Based on Dose Strength, market is studied across 250000 Unit and 5000 Unit.
  • Based on Indication, market is studied across Catheter Clearance, Coronary Artery Thrombosis, Deep Vein Thrombosis, and Pulmonary Embolism.
  • Based on Application, market is studied across Hospital, Research Institutions, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of pulmonary embolism and coronary artery thrombosis worldwide=
      • 5.1.1.2. Supportive government approvals for urokinase-based medications
    • 5.1.2. Restraints
      • 5.1.2.1. High costs of drug development and availability of alternatives
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing research and development to improve the applicability of urokinase
      • 5.1.3.2. Adoption of advanced drug delivery systems to enhance the effectiveness of urokinase-based treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Side effects associated with urokinase-based drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Significant preference towards urokinase powder due to superior shelf life
    • 5.2.2. Application: Expanding application of urokinase in hospitals as a pivotal therapeutic agent
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Urokinase Market, by Type

  • 6.1. Introduction
  • 6.2. Urokinase Powder
  • 6.3. Urokinase Solution

7. Urokinase Market, by Dose Strength

  • 7.1. Introduction
  • 7.2. 250000 Unit
  • 7.3. 5000 Unit

8. Urokinase Market, by Indication

  • 8.1. Introduction
  • 8.2. Catheter Clearance
  • 8.3. Coronary Artery Thrombosis
  • 8.4. Deep Vein Thrombosis
  • 8.5. Pulmonary Embolism

9. Urokinase Market, by Application

  • 9.1. Introduction
  • 9.2. Hospital
  • 9.3. Research Institutions
  • 9.4. Specialty Clinics

10. Americas Urokinase Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Urokinase Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Urokinase Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Strategic Alliance Revives Kinlytic: A Milestone in Thrombolytic Therapy
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. BBT Biotech GmbH
  • 3. Cerbios-Pharma SA
  • 4. Echelon Biosciences
  • 5. Ilex Life Sciences LLC
  • 6. JCR Pharmaceuticals Co., Ltd.
  • 7. Jiangsu Aidea Pharmaceutical Co., Ltd
  • 8. Jiangxi Haoran Bio-pharma Co., Ltd.
  • 9. Kraeber & Co GmbH
  • 10. Merck KGaA
  • 11. Microbix Biosystems Inc.
  • 12. Midas Pharma GmbH
  • 13. Pfizer Inc.
  • 14. Syner-Med Pharmaceuticals
  • 15. Taj Pharmaceuticals Ltd.
  • 16. Thermo Fisher Scientific Inc.
  • 17. VWR International, LLC
  • 18. Wanhua Biochem Products Co. Ltd.
  • 19. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. UROKINASE MARKET RESEARCH PROCESS
  • FIGURE 2. UROKINASE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL UROKINASE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL UROKINASE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL UROKINASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL UROKINASE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL UROKINASE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL UROKINASE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL UROKINASE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL UROKINASE MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL UROKINASE MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS UROKINASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS UROKINASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES UROKINASE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES UROKINASE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC UROKINASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC UROKINASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. UROKINASE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. UROKINASE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. UROKINASE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL UROKINASE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL UROKINASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL UROKINASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. UROKINASE MARKET DYNAMICS
  • TABLE 7. GLOBAL UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL UROKINASE MARKET SIZE, BY UROKINASE POWDER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL UROKINASE MARKET SIZE, BY UROKINASE SOLUTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL UROKINASE MARKET SIZE, BY 250000 UNIT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL UROKINASE MARKET SIZE, BY 5000 UNIT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL UROKINASE MARKET SIZE, BY CATHETER CLEARANCE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL UROKINASE MARKET SIZE, BY CORONARY ARTERY THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL UROKINASE MARKET SIZE, BY DEEP VEIN THROMBOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL UROKINASE MARKET SIZE, BY PULMONARY EMBOLISM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL UROKINASE MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL UROKINASE MARKET SIZE, BY RESEARCH INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL UROKINASE MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS UROKINASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES UROKINASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC UROKINASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA UROKINASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM UROKINASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM UROKINASE MARKET SIZE, BY DOSE STRENGTH, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM UROKINASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM UROKINASE MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 190. UROKINASE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. UROKINASE MARKET, FPNV POSITIONING MATRIX, 2023